Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Retained Earnings (2017 - 2026)

Denali Therapeutics has reported Retained Earnings over the past 9 years, most recently at -$2.1 billion for Q4 2025.

  • Quarterly Retained Earnings fell 33.3% to -$2.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.1 billion through Dec 2025, down 33.3% year-over-year, with the annual reading at -$2.1 billion for FY2025, 33.3% down from the prior year.
  • Retained Earnings was -$2.1 billion for Q4 2025 at Denali Therapeutics, down from -$1.9 billion in the prior quarter.
  • Over five years, Retained Earnings peaked at $5.5 million in Q3 2024 and troughed at -$2.1 billion in Q4 2025.
  • The 5-year median for Retained Earnings is -$248.7 million (2021), against an average of -$606.1 million.
  • The largest YoY upside for Retained Earnings was 949.31% in 2024 against a maximum downside of 239444.32% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$645.0 million in 2021, then soared by 98.93% to -$6.9 million in 2022, then soared by 109.34% to $643000.0 in 2023, then crashed by 239444.32% to -$1.5 billion in 2024, then crashed by 33.3% to -$2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Retained Earnings are -$2.1 billion (Q4 2025), -$1.9 billion (Q3 2025), and -$1.8 billion (Q2 2025).